Importance of soluble cytokine receptors for inflammation associated cancer
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 8
Abstract
Cytokine receptors, which exist in membrane-bound and soluble form, bind their ligands with comparable affinity. While most soluble receptors are antagonists in that they compete for the ligands with their membrane counterparts, some soluble receptors are agonists. In this case, the complex of ligand and soluble receptor binds on target cells to a second receptor subunit and initiates signal transduction. The soluble receptors of the IL-6 family of cytokines (sIL-6R, sIL-11R, sCNTF-R) are agonists. In vivo, the IL-6/soluble IL-6R complex stimulates several types of target cells not stimulated by IL-6 alone, since they do not express membrane-bound IL-6R. This process has been named transsignalling. We have shown that in several chronic inflammatory diseases such as chronic inflammatory bowl disease, peritonitis and rheumatoid arthritis, transsignalling via soluble IL-6R complexed to IL-6 is a crucial point in the transition from the acute to the chronic state of the disease. The mechanism by which the IL-6/ soluble IL-6R complex regulates the inflammatory state is discussed.
Authors and Affiliations
Stefan Rose-John
Keywords
Related Articles
- EP ID EP112835
- DOI -
- Views 72
- Downloads 0
Adjuvant endocrine therapy in breast cancer
Endocrine therapy is the most important component of adjuvant therapy for patients with hormone receptor-positive breast cancer, regardless of age and menopausal status. Tamoxifen improves survival in premenopausal and...
New agents in treatment of metastatic renal cell carcinoma
As renal cell carcinoma appears to be resistant to conventional treatment modalities and results of cytokine-based immunotherapy are far from satisfactory, there is desperate need for new active agents to be discovered....
Jakość życia osób ze stomią jelitową
Ratowanie życia coraz większej rzeszy ludzi w wieku podeszłym, często chorych i niepełnosprawnych, stało się triumfem wiedzy i techniki medycznej z jednej strony, a z drugiej wyzwaniem, polegającym na doprowadzeniu urato...
Report from the 4-th International Symposium on Targeted Anticancer Therapies, Amsterdam March 16-18, 2006 (TAT 2006)
Nowe leki stosowane w leczeniu przerzutowego raka nerki
Ze względu na oporność przerzutowego raka nerki na konwencjonalne metody leczenia trwają poszukiwania nowych leków. Immunoterapia, bazująca na interferonie alfa, uznawana za nieformalny standard postępowania w leczeniu s...